EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Leadless atrial versus transvenous pacing for sinus node dysfunction: 1-year outcomes from the leadless ARRIVE real-world study

Kent R Nilsson iD, Ulrika Birgersdotter-Green, Shmaila Saleem-Talib iD, Deepti Bettampadi iD, Zeyuan Yang, Jorge O Diaz iD, James K Gabriels iD, Robert D Schaller iD, Himanshu H Shukla iD, Michael Kühne iD, Mauro Biffi iD, Daniel Hofer iD und 3 weitere

Europace · 2026

DOI: 10.1093/europace/euag072 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Europace, 2026. Verfasst von Kent R Nilsson und 14 weiteren Autor:innen. Beteiligte Einrichtung: Piedmont Heart Institute, Athens, GA, USA. Hauptthemen laut MEDLINE: Sick Sinus Syndrome, Pacemaker, Artificial, Cardiac Pacing, Artificial. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Abbott Laboratories.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Leadless pacing was developed to avoid complications inherent to transvenous (TV) pacemakers. Among patients with sinus node dysfunction (SND) without atrioventricular block (AVB), TV systems remain standard therapy. Real-world data have shown favourable safety profiles for leadless vs. TV pacemakers. This study aimed to compare 30-day complications and 1-year outcomes—including complications, device-reinterventions, and all-cause mortality—between AVEIR AR leadless pacemakers (LP) and dual-chamber (DCTV) or right-atrial (RATV) TV pacemakers.

Methods

Medicare fee-for-service claims were analysed to identify patients undergoing de novo AVEIR AR LP or TV pacemaker implantation from January 2024 to March 2025, with ≥1 year of prior and ≥30 days of post-implant continuous enrolment. The DCTV cohort included patients with SND without permanent atrial fibrillation or AVB; the RATV and LP cohorts included all respective recipients. Outcomes included 30-day and 1-year complications, device-reinterventions, and mortality. Comparisons were adjusted using propensity score derived overlap weights.

Results

A total of 428 AVEIR AR, 39 881 DCTV, and 389 RATV patients were included. Thirty-day complications were lower with AVEIR AR compared with DCTV (adjusted 6.7% vs. 9.4%; OR = 0.7) and similar to RATV (6.9% vs. 6.7%). At 1 year, overall complications remained lower in AVEIR AR than DCTV (3.6% vs. 8.5%; HR = 0.4) and RATV (3.3% vs. 7.5%; HR = 0.4) cohorts. Device-related complications were reduced vs. DCTV, and reinterventions were reduced vs. both DCTV and RATV. Mortality was comparable across all groups.

Conclusion

AVEIR AR was associated with fewer long-term complications and reinterventions compared with DCTV and RATV, while 1-year mortality remained similar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sick Sinus SyndromePacemaker, ArtificialCardiac Pacing, ArtificialFemaleHumansMaleAgedTreatment OutcomeAged, 80 and overUnited StatesEquipment DesignTime FactorsRetrospective Studies

Stichwörter der Autor:innen

AVEIRAtrial pacemakersOutcomesReinterventionsSafetyTransvenous pacemakers

Autor:innen und Institutionen

  • Piedmont Heart Institute, Athens, GA, USA.
  • UC San Diego Health, San Diego, CA, USA.
  • HagaZiekenhuis, The Hague, Netherlands.
  • Global Data Science and Analytics, Abbott Laboratories, Santa Clara, CA, USA.
  • HCA Florida Lake Monroe Hospital, Lake Monroe, FL, USA.
  • Northwell Cardiovascular Institute, North Shore University Hospital, New Hyde Park, NY, USA.

ORCID-Profile: Kent R Nilsson, Shmaila Saleem-Talib, Deepti Bettampadi, Jorge O Diaz, James K Gabriels, Robert D Schaller, Himanshu H Shukla, Michael Kühne, Mauro Biffi, Daniel Hofer, Yelena Nabutovsky, Christophe Garweg

Förderung

  • Abbott Laboratories

Zitieren

APA

Nilsson, K. R., Birgersdotter-Green, U., Saleem-Talib, S., Bettampadi, D., Yang, Z., Diaz, J. O., Gabriels, J. K., Schaller, R. D., Shukla, H. H., Kühne, M., Biffi, M., Hofer, D., Paisey, J., Nabutovsky, Y., & Garweg, C. (2026). Leadless atrial versus transvenous pacing for sinus node dysfunction: 1-year outcomes from the leadless ARRIVE real-world study. Europace. https://doi.org/10.1093/europace/euag072

Vancouver

Nilsson KR, Birgersdotter-Green U, Saleem-Talib S, Bettampadi D, Yang Z, Diaz JO, et al. Leadless atrial versus transvenous pacing for sinus node dysfunction: 1-year outcomes from the leadless ARRIVE real-world study. Europace. 2026. doi:10.1093/europace/euag072

BibTeX
@article{Nilsson2026,
  author = {Nilsson, Kent R and Birgersdotter-Green, Ulrika and Saleem-Talib, Shmaila and Bettampadi, Deepti and Yang, Zeyuan and Diaz, Jorge O and Gabriels, James K and Schaller, Robert D and Shukla, Himanshu H and Kühne, Michael and Biffi, Mauro and Hofer, Daniel and Paisey, John and Nabutovsky, Yelena and Garweg, Christophe},
  title = {Leadless atrial versus transvenous pacing for sinus node dysfunction: 1-year outcomes from the leadless ARRIVE real-world study},
  journal = {Europace},
  year = {2026},
  doi = {10.1093/europace/euag072}
}
Kostenlos starten →